

The ins and outs of engineering functional tissues and organs

Citation for published version (APA):

Kurniawan, N. (2019). The ins and outs of engineering functional tissues and organs: evaluating the in-vitro and in-situ processes. *Current Opinion in Organ Transplantation*, 24(5), 590-597.
<https://doi.org/10.1097/MOT.0000000000000690>

DOI:

[10.1097/MOT.0000000000000690](https://doi.org/10.1097/MOT.0000000000000690)

Document status and date:

Published: 01/10/2019

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.



The ins and outs of engineering functional tissues and organs: evaluating the in-vitro and in-situ processes

Nicholas A. Kurniawan^{a,b}

Purpose of review

For many disorders that result in loss of organ function, the only curative treatment is organ transplantation. However, this approach is severely limited by the shortage of donor organs. Tissue engineering has emerged as an alternative solution to this issue. This review discusses the concept of tissue engineering from a technical viewpoint and summarizes the state of the art as well as the current shortcomings, with the aim of identifying the key lessons that we can learn to further advance the engineering of functional tissues and organs.

Recent findings

A plethora of tissue-engineering strategies have been recently developed. Notably, these strategies put different emphases on the in-vitro and in-situ processes (i.e. preimplantation and postimplantation) that take place during tissue formation. Biophysical and biomechanical interactions between the cells and the scaffold/biomaterial play a crucial role in all steps and have started to be exploited to steer tissue regeneration.

Summary

Recent works have demonstrated the need to better understand the in-vitro and in-situ processes during tissue formation, in order to regenerate complex, functional organs with desired cellular organization and tissue architecture. A concerted effort from both fundamental and tissue-specific research has the potential to accelerate progress in the field.

Keywords

bioreactor, cell–matrix interactions, in-situ tissue engineering, scaffold-free tissue engineering, tissue regenerative constructs

INTRODUCTION

The past two decades have seen the emergence of tissue engineering as a promising solution for alleviating the massive disparity between the demand for organs for transplantation and the available supply of organs in the clinic [1,2]. Tissue engineering proposes an alternative concept of building and regenerating tissues and organs for transplantation from their components: cells and/or (bio)materials. As these components can be made available and prepared in the laboratory, this concept can potentially yield an unlimited and even patient-specific source of tissues and organs, thereby relieving the problem of organ shortage.

Tissue engineering has been applied to engineer various organs and tissues with diverse functionalities, from kidney, tendon, and cornea to blood vessels and the heart. These applications to engineering specific organs and tissues have been separately and extensively addressed in excellent recent reviews (see, e.g. [3–6]). In this opinion article, we will instead focus on the technological perspective, take a bird's-eye view of the

major tissue engineering strategies that have been recently developed, identify the common denominators as well as the unique strengths and limitations, and critically evaluate the principal challenges and opportunities that lie ahead. As will become clear, progress in the field requires a concerted effort to look more closely into the fundamental biophysical and biomechanical

^aDepartment of Biomedical Engineering and ^bInstitute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands

Correspondence to Nicholas A. Kurniawan, PhD, Department of Biomedical Engineering, Eindhoven University of Technology, P.O. Box 513, 5600 MB Eindhoven, The Netherlands. Tel: +31 40 247 2347; e-mail: kurniawan@tue.nl

Curr Opin Organ Transplant 2019, 24:590–597

DOI:10.1097/MOT.0000000000000690

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

KEY POINTS

- Tissue engineering holds the potential of rebuilding new, functional tissues and organs.
- Tissue engineering involves in-vitro and in-situ steps, both of which need to be carefully designed and tailored to achieve tissue function.
- Biophysical and biomechanical interactions between cells and the scaffold or biomaterials play a crucial role in both the in-vitro and in-situ steps of tissue engineering.
- Future studies are expected to deepen our understanding of dynamic cell–matrix interactions as well as to develop innovative ways to mimic and exploit these interactions for steering tissue growth and remodeling.

processes that occur preimplantation (*in vitro*) and postimplantation (*in situ*), in order to construct an efficient and sustainable engineering methodology for achieving functional tissue and organ regeneration.

TISSUE ENGINEERING STRATEGIES

Various tissue engineering strategies have been devised and developed over the years. Here we

classify and briefly summarize these strategies based on the ingredients that are used as a starting point for regenerating the tissue (Fig. 1 and Table 1).

‘Conventional’ tissue engineering

The ‘conventional’ tissue engineering methods use a combination of cells and scaffolds or matrices as a starting point. The first step is obtaining tissue-matching cells, either from primary source (i.e. the patient) or from stem cells (e.g. embryonic stem cells and stromal cells derived from adult bone marrow or umbilical cord). After in-vitro expansion, the cells are seeded onto or into the scaffold and encouraged to populate the scaffold and to produce their own extracellular matrix as a foundation of a tissue for transplantation. Finally, the engineered tissue is implanted. In this approach, the entire tissue engineering process takes place *in vitro*.

The first component is the cells – the producer of the new tissue. Primary autologous cells have provided substantial success as they have the advantage of being taken directly from the tissue source, hence preventing adverse immune response, are fully differentiated, and readily produce tissue-specific extracellular matrix (ECM) [7]. However, these cells require invasive cell collection, suffer from low proliferative capacity, which may be further limited with increasing donor




FIGURE 1. The workflow of major classes of tissue-engineering strategies. It is important to note that achieving functional tissues and organs involve processes that take place both *in vitro* and *in situ*. In both steps, cells are in continuous dynamic interactions and adapt to the cues provided by their environments.

Table 1. Characteristics of major tissue engineering strategies

Aspect	Conventional tissue engineering	Scaffold-free tissue engineering	Bioprinting	Cell-free tissue engineering
In-vitro and in-situ steps	Cells, scaffold (and other desired molecules)	Cells	Cells, biomaterial (and other desired molecules)	Scaffold
Cell introduction	In-vitro seeding into scaffold	Cells present initially	Cells present initially	In-situ recruitment
Extracellular matrix	Fabricated solid materials or decellularized tissues + in-vitro cell secretion	In-vitro cell secretion	Present in the bioink and in-vitro cell secretion	In-situ cell secretion
Tissue formation	<i>In vitro</i> (bioreactor)	<i>In vitro</i>	<i>In vitro</i>	<i>In situ</i>
Implanted product	Cell-seeded scaffold	Assembled tissue building blocks	3D-printed tissue	Cell-free scaffold
Postimplantation	Scaffold degradation, neotissue maturation	Fusion with host tissue, neotissue maturation	Fusion with host tissue, neotissue maturation	Host response, cell recruitment, matrix degradation, scaffold formation, tissue maturation
Potential clinical availability	Moderate	Slow	Moderate	Fast, even off-the-shelf
In-vitro complexity	Moderate, labor-intensive and time-consuming preparation	High, especially for the assembly of the building blocks	Moderate, especially on the optimization of bioink	Low, mostly in terms of scaffold design
Advantages	Diverse choice of materials and scaffold fabrication, advanced control of microstructure and architecture	Possibility to recreate tissues with complex architecture	High-resolution placement of cells in tissue constructs with complex architecture	Low cost, simpler regulation for clinical translation, harnesses body's own regenerative capacity
Common issues	Heterogeneous cell distribution	Fragile cell constructs, inadequate mechanical properties	Requires dedicated devices, high-performance bioinks, high-resolution printing	Unpredictable host response, fibrotic response
Ideal applications	Load-bearing tissues, soft and hard tissues, disease modeling, drug screening	Tissues with defined structure, disease modeling	Tissues with defined structure, vascularized tissues, disease modeling	Vascularized tissues

age, and carry the risk of the cells being in a diseased state [8,9]. The use of stem cells circumvents many of these drawbacks, although it requires additional steps of isolating the stem cells, ensuring complete differentiation or removal of all stem cells prior to transplantation, and demonstrating the absence of teratoma formation *in vivo* because of the cells' inherent oncogenic potential [10,11].

The second component is the scaffold. The original purpose of the scaffold matrices in tissue engineering is to provide a temporary structural support for the cells. It is typically a fabricated three-dimensional construct with interconnected pores, a hydrogel, or a decellularized ECM of a tissue [12]. The scaffold consists of biocompatible and biodegradable synthetic or biological materials and will be replaced by the new ECM produced by the cells. Later, it was realized that the scaffold can be used to deliver growth factors that promote cell recruitment, proliferation, and matrix deposition, thereby aiding neotissue formation. This has led to extensive research investigating the utility of including modifying factors, such as biologically active proteins, drugs, and DNA in the scaffolds for tissue engineering [13,14,15–18]. More recently, it has also been recognized that the physical, structural, and mechanical properties of the scaffold alone (i.e. even in the absence of chemical factors) can direct a wide range of cell behaviors [19–24]. On the one hand, this opens up a wide array of possibilities to rationally design 3D scaffold structures with cell-instructive properties, exploiting the rapid advance of high-resolution scaffold fabrication techniques, to further promote directed cell infiltration and tissue formation [25]. On the other hand, this highlights the need to carefully tune the physical properties of the scaffold, not only to maintain its mechanical integrity, but also to ensure adequate cell infiltration, differentiation, and tissue formation after implantation.

Scaffold-free tissue engineering

A scaffold-free tissue engineering approach has also been widely explored, where the idea is to obtain engineered tissues directly by assembling cells without the help of scaffolds. To bridge the gap in length scale between single cells and transplantable tissues and organs, the process is typically divided into two steps: prefabrication of multicellular building blocks and assembly of these building blocks into macroscopic tissues. Because of this modular approach, scaffold-free tissue engineering is also sometimes called 'modular' tissue engineering [26]. Similar to conventional tissue engineering, here the entire tissue engineering process also takes place *in vitro*.

The type of the building blocks from which the tissue is assembled defines several scaffold-free tissue engineering strategies. A common method is to use cell spheroids or aggregates, which are usually produced by subjecting cell cultures to rotational forces or flows, whose speed and duration can be tuned to control the size of the resulting aggregates [27,28]. The aggregates can then be implanted directly or coalesced to form larger tissue structures. Another method is using cell sheets [29]. Cells are expanded until a confluent monolayer with significant amount of ECM is obtained, allowing the cell sheet to be lifted from the surface as a whole [30]. The use of stimuli-responsive materials as culture substrate allows the cell–cell junctions and the deposited ECM to be preserved during lifting [31]. The released cell sheets can then be manipulated by stacking, layering, or draping over molds to achieve thick multilayered tissues [32]. The building blocks can also be obtained using self-assembly methods [33]. Here, cells are cultured in a non-cell-adherent mold and allowed to interact with each other, coalesce, and produce their own ECM. As no external forces are introduced to the culture, the tissue formation is argued to better mimic developmental processes.

A shared advantage of these scaffold-free tissue engineering methods is that they bypass the practical issues related to the scaffolds, including the design and fabrication of the scaffold as well as cell seeding, proliferation, and migration into the scaffold. However, the lack of scaffold also carries the drawback that both the cell-based building blocks and the final tissue constructs are often mechanically fragile and prone to damage during manipulation [34]. Moreover, the scaffold-free tissue engineering methods usually require extended time to obtain sufficient number of cells and to ensure fusion of the building blocks to obtain cohesive tissue constructs. The major strength of scaffold-free tissue engineering approach is the superior control over tissue architecture, enabled by controlled assembly and placement of building blocks consisting of different cell types. In fact, there is a growing momentum to develop techniques that combine the strengths of scaffold-based and scaffold-free approaches (reviewed in [35]).

Bioprinting

A unique strategy has been developed to exploit the technological advances of additive manufacturing while at the same time retaining the spatial control of scaffold-free tissue engineering approaches: bioprinting. The concept is to deposit suspensions containing cells as well as hydrogels, biomaterials, growth factors, and any other desired bioactive

molecules ('bioink') in a spatially controlled manner ('printing') to achieve 3D tissue-like architectures [36,37]. The components and composition of the bioink can be chosen to resemble the conventional tissue engineering approach using degradable (natural or synthetic) hydrogels or polymers, or to resemble the 'scaffold-free' tissue engineering approach by directly printing cell aggregates [38]. Here, again, the complete tissue formation process takes place *in vitro*.

The main critical aspects are choosing the bioink with the desired rheological properties and gelation kinetics to ensure its printability [39,40], optimizing the printing strategies and parameters that match the properties of the bioink [41], and ensuring fusion and validating the resulting construct structure and cell viability [42]. The major strength of bioprinting is its ability to control placement of cells within a 3D tissue-like constructs.

Cell-free tissue engineering

A diametrically opposite approach of the scaffold-free tissue engineering has also recently emerged: cell-free tissue engineering. This approach focuses on endogenous regeneration of the damaged tissue, aided by acellular bioresorbable scaffolds that are implanted in the functional site [43]. The underlying hypothesis in this approach is that the host response to the implanted scaffold can be steered to induce regeneration of the functional tissue [44,45]. The complete tissue formation process occurs *in situ*, hence the approach is also known as 'in-situ TE'.

The absence of cells allows cell-free tissue engineering to bypass all issues related to cell sourcing and seeding, simplifies regulatory hurdles, allows quick and off-the-shelf availability of treatments, and eliminates the time-consuming and labor-intensive process of in-vitro tissue formation [46]. The main challenge is scaffold design. In particular, all aspects of the scaffold, from its material composition, microstructure, surface chemistry, topography, bioactivity, mechanical properties, degradation profile, to its gross macroscopic morphology, must be precisely designed and tailored *in vitro* to induce the right tissue-specific responses *in vivo*. These responses include the recruitment and infiltration of the desired (progenitor) cells, differentiation and polarization of the cells, matrix deposition, and the functional maintenance of the tissue construct. Importantly, all of these steps need to be taken into consideration in the complex in-situ context, for example, foreign-body reaction and the associated immune response, contact with blood flow, and local mechanical stretching of the tissue.

PUSHING THE (IN-VITRO AND IN-SITU) BOUNDARIES

The ultimate goal of tissue engineering is to regenerate tissue function at the affected site. Different elements that are needed for tissue function have started to be tackled, primarily in terms of cellular composition and tissue architecture. Looking ahead, we reflect on the in-vitro and in-situ focus points that represent the outstanding scientific challenges and exciting technological possibilities in tissue engineering for the near future.

In vitro: controlling cell organization to achieve tissue function

In-vitro tissue engineering has made considerable advances in obtaining tissue constructs with the desired cell compositions and complex tissue architectures. One of the most critical next challenges is to achieve organization at the cell level, which is especially crucial for the physiological function of mechanically active tissues like the cardiovascular and musculoskeletal tissues [47]. The challenge is two-fold: understanding the fundamental principles underlying cellular organization in native, living tissues, and figuring out ways to manipulate cellular organization in engineered tissues and organs. Importantly, cellular organization is known to be governed by the local cell-matrix physical and mechanical interactions, through processes, such as contact guidance [48–50], strain avoidance [51,52], flow-induced alignment [53,54], and curvature avoidance [55–57]. Although the molecular mechanisms underlying such processes are currently still intensely debated [58], from a tissue engineering perspective, these phenomena provide an attractive avenue for achieving tissue ordering and organization at the cell scale.

In the context of scaffold-based tissue engineering, this is possible by designing scaffolds that provide cells with specific cues like fiber size, pore size, mechanical properties, and overall geometry [59] – parameters that can be finely tuned using today's scaffold fabrication techniques (e.g. rapid prototyping, electrospinning/writing) [60], even in combination with additional environmental cues [61,62]. For scaffold-free tissue engineering, cell organization can potentially be achieved by micropatterning the multicellular building blocks, for example, aided by nanotopography/microtopography and DNA or ligand printing [63,64]. Fundamental research on cellular response to these local cues using minimal models is clearly poised to strongly accelerate efficient optimization of the experimental parameters in achieving this high-resolution cellular organization [65]. It is envisioned that this exciting




FIGURE 2. Cell and tissue response is sensitively dependent on cues and stimulation present in their environment. For tissue engineering purposes, these in-situ cues and stimulations can be mimicked and exploited *in vitro* to steer functional tissue formation and regeneration.

development will pave the way to engineered autologous tissues and organs that are as function-ready as possible for transplantation.

***In situ*: understanding, recreating, and steering tissue remodeling**

Urged by the obvious role of the biophysical and biomechanical interactions between cells and the cellular environment in tissue formation and function, there has been a growing need for experimental platforms that allow one to subject cells and tissue constructs to a variety of biomimetic physical and mechanical cues in a controllable manner – ‘bioreactors’ [66,67]. By providing culture conditions that closely recapitulate the environmental conditions of the native/desired tissues (Fig. 2), the hypotheses are that bioreactors can promote the formation and growth of viable tissues and organs for the in-vitro steps of tissue engineering [68] and that bioreactors can help us predict and steer tissue formation and evolution for the in-situ steps of tissue engineering in the presence of passive and active cues from the cellular microenvironment [69].

In addition to improving the existing bioreactors to further fine tune the in-vitro culture conditions of the tissue constructs, two promising research directions have started to be explored. First, in most in-vivo environments, multiple cues are simultaneously at work, but the combinatorial effects of multiple environmental cues on cells and

tissues are still poorly understood. Smart designs of bioreactors will allow decoupling of such cue combinations and help bridge our fundamental understanding of cell response (typically to single cues) and physiological tissue functions. For example, recent development of bioreactors that allow decoupling of mechanical stretch and shear flow demonstrates that these cues act nonsynergistically in regulating cell–cell signaling [70], cell proliferation [71], and neovessel formation [72], highlighting the need to better understand the underlying mechanisms of tissue growth. Second, bioreactors endow us with the possibility of quantitatively controlling the cues in a spatiotemporally resolved manner. When combined with physiologically relevant scaffold and tissue geometries, this has an enormous potential for disease modeling and drug screening. For example, by simulating different in-vivo conditions *in vitro*, one can mechanistically identify the possible causes of the disease and test different therapeutic strategies systematically [73].

CONCLUSION

Research over the past few years has not only demonstrated significant advances in each of the TE approaches, but has also resulted in new, innovative strategies and methodologies that are designed to overcome the limitations of the existing methods. This strong technological progress has the potential to elevate the physiological functionality of the

engineered tissues, to broaden the application areas (i.e. the possibility to engineer more diverse tissues and organs), and to increase the clinical accessibility and robustness of the engineered constructs (e.g. by simplifying the constructs in view of the ethical, social, and regulatory concerns). At the same time, fundamental research on cell–matrix and cell–material interactions has proven to be vital in deepening our understanding of the in-vitro and in-situ processes during tissue formation and remodeling. A concerted effort in these basic and technologically oriented research lines will enable a more directed, hypothesis-based tissue engineering and away from inefficient trial-based and error-based approach.

Acknowledgements

The author would like to thank members of the Soft Tissue Engineering and Mechanobiology group for insightful discussions.

Financial support and sponsorship

This work is supported by the Gravitation Program 'Materials-Driven Regeneration' by the Ministry of Education, Culture and Science of The Netherlands.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Langer R, Vacanti JP. Tissue engineering. *Science* 1993; 260:920–926.
2. Shafiee A, Atala A. Tissue engineering: toward a new era of medicine. *Annu Rev Med* 2017; 68:29–40.
3. Song HHG, Rumma RT, Ozaki CK, *et al.* Vascular tissue engineering: progress, challenges, and clinical promise. *Cell Stem Cell* 2018; 22:340–354.
4. Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering: state of the art. *Circ Res* 2014; 114:354–367.
5. González-Quevedo D, Martínez-Medina I, Campos A, *et al.* Tissue engineering strategies for the treatment of tendon injuries. *Bone Joint Res* 2018; 7:318–324.
6. Ghezzi CE, Rnjak-Kovacina J, Kaplan DL. Corneal tissue engineering: recent advances and future perspectives. *Tissue Eng Part B Rev* 2014; 21:278–287.
7. Bajpai VK, Andreadis ST. Stem cell sources for vascular tissue engineering and regeneration. *Tissue Eng Part B Rev* 2012; 18:405–425.
8. Siegel G, Kluba T, Hermanutz-Klein U, *et al.* Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. *BMC Med* 2013; 11:146.
9. Strässler ET, Aalto-Setälä K, Kiamehr M, *et al.* Age is relative—Impact of donor age on induced pluripotent stem cell-derived cell functionality. *Front Cardiovasc Med* 2018; 5:4.
10. Howard D, Buttery LD, Shakesheff KM, Roberts SJ. Tissue engineering: strategies, stem cells and scaffolds. *J Anat* 2008; 213:66–72.
11. Bedel A, Beliveau F, Lamrissi-Garcia I, *et al.* Preventing pluripotent cell teratoma in regenerative medicine applied to hematology disorders. *Stem Cells Transl Med* 2017; 6:382–393.
12. O'Brien FJ. Biomaterials & scaffolds for tissue engineering. *Mater Today* 2011; 14:88–95.
13. Tibbitt MW, Rodell CB, Burdick JA, Anseth KS. Progress in material design for biomedical applications. *Proc Natl Acad Sci USA* 2015; 112:14444–14451.

14. Koçer G, Jonkheijm P. About chemical strategies to fabricate cell-instructive ■ biointerfaces with static and dynamic complexity. *Adv Healthc Mater* 2018; 7:1–32.

This article critically discusses experimental strategies to design biomaterials and scaffolds with either static or dynamic (i.e. stimuli-responsive) properties, which can be used not only to direct cell behavior but also to deepen our understanding of cell–material interactions.

15. Martins C, Sousa F, Araújo F, Sarmiento B. Functionalizing PLGA and PLGA derivatives for drug delivery and tissue regeneration applications. *Adv Healthc Mater* 2018; 7:1701035.
16. Tian T, Xie W, Gao W, *et al.* Micro-nano bioactive glass particles incorporated porous scaffold for promoting osteogenesis and angiogenesis in vitro. *Front Chem* 2019; 7:186.
17. Galindo TGP, Chai Y, Tagaya M. Hydroxyapatite nanoparticle coating on polymer for constructing effective biointeractive interfaces. *J Nanomater* 2019; 2019:1–23.
18. Madrigal JL, Shams S, Stilhano RS, Silva EA. Characterizing the encapsulation and release of lentivectors and adeno-associated vectors from degradable alginate hydrogels. *Biomater Sci* 2019; 7:645–656.
19. Charras G, Sahai E. Physical influences of the extracellular environment on cell migration. *Nat Rev Mol Cell Biol* 2014; 15:813–824.
20. Van Helvert S, Storm C, Friedl P. Mechanoreciprocity in cell migration. *Nat Cell Biol* 2018; 20:8–20.
21. Kurniawan NA, Chaudhuri PK, Lim CT. Mechanobiology of cell migration in the context of dynamic two-way cell–matrix interactions. *J Biomech* 2016; 49:1355–1368.
22. Sun M, Chi G, Li P, *et al.* Effects of matrix stiffness on the morphology, adhesion, proliferation and osteogenic differentiation of mesenchymal stem cells. *Int J Med Sci* 2018; 15:257–268.
23. Bruekers SM, Jaspers M, Hendriks JM, *et al.* Fibrin-fiber architecture influences cell spreading and differentiation. *Cell Adh Migr* 2016; 10:495–504.
24. Grier WK, Iyoha EM, Harley BAC. The influence of pore size and stiffness on tenocyte bioactivity and transcriptomic stability in collagen-GAG scaffolds. *J Mech Behav Biomed Mater* 2017; 65:295–305.
25. Huang G, Li F, Zhao X, *et al.* Functional and biomimetic materials for ■ engineering of the three-dimensional cell microenvironment. *Chem Rev* 2017; 117:12764–12850.

A comprehensive, state-of-the-art review on various approaches to design and modify biomaterials to modulate cell response.

26. Nichol JW, Khademhosseini A. Modular tissue engineering: engineering biological tissues from the bottom up. *Soft Matter* 2009; 5:1312–1319.
27. Moldovan L, Barnard A, Gil C-H, *et al.* iPSC-derived vascular cell spheroids as building blocks for scaffold-free biofabrication. *Biotechnol J* 2017; 12:1700444.
28. Cui X, Hartanto Y, Zhang H. Advances in multicellular spheroids formation. *J R Soc Interface* 2017; 14:20160877.
29. L'Heureux N, Pâquet S, Labbé R, *et al.* A completely biological tissue-engineered human blood vessel. *FASEB J* 1998; 12:47–56.
30. Haraguchi Y, Shimizu T, Yamato M, Okano T. Scaffold-free tissue engineering using cell sheet technology. *RSC Adv* 2012; 2:2184–2190.
31. Li M, Ma J, Gao Y, Yang L. Cell sheet technology: a promising strategy in regenerative medicine. *Cytotherapy* 2019; 21:3–16.
32. Kim MS, Lee B, Kim HN, *et al.* 3D tissue formation by stacking detachable cell sheets formed on nanofiber mesh. *Biofabrication* 2017; 9: 015029.
33. Saba I, Jakubowska W, Bolduc S, Chabaud S. Engineering tissues without the use of a synthetic scaffold: a twenty-year history of the self-assembly method. *Biomed Res Int* 2018; 2018:1–13.
34. Schon BS, Hooper GJ, Woodfield TB. Modular tissue assembly strategies for biofabrication of engineered cartilage. *Ann Biomed Eng* 2017; 45:100–114.
35. Ovsianikov A, Khademhosseini A, Mironov V. The synergy of scaffold-based and scaffold-free tissue engineering strategies. *Trends Biotechnol* 2018; 36:348–357.
36. Zhang YS, Yue K, Aleman J, *et al.* 3D bioprinting for tissue and organ fabrication. *Ann Biomed Eng* 2017; 45:148–163.
37. Cui H, Miao S, Esworthy T, *et al.* 3D bioprinting for cardiovascular regeneration and pharmacology. *Adv Drug Deliv Rev* 2018; 132:252–269.
38. Moldovan NI, Hibino N, Nakayama K. Principles of the Kenzan method for robotic cell spheroid-based three-dimensional bioprinting. *Tissue Eng Part B Rev* 2017; 23:237–244.
39. Jia W, Gungor-Ozkerim PS, Zhang YS, *et al.* Direct 3D bioprinting of perfusable vascular constructs using a blend bioink. *Biomaterials* 2016; 106:58–68.
40. Gao T, Gillispie GJ, Copus JS, *et al.* Optimization of gelatin-alginate composite bioink printability using rheological parameters: a systematic approach. *Biofabrication* 2018; 10:034106.
41. Gao G, Kim BS, Jang J, Cho DW. Recent strategies in extrusion-based three-dimensional cell printing toward organ biofabrication. *ACS Biomater Sci Eng* 2019; 5:1150–1169.
42. Moldovan NI. Progress in scaffold-free bioprinting for cardiovascular medicine. *J Cell Mol Med* 2018; 22:2964–2969.

43. Wissing TB, Bonito V, Bouten CVC, Smits ALPM. Biomaterial-driven in situ cardiovascular tissue engineering—a multidisciplinary perspective. *npj Regen Med* 2017; 2:18.
44. Rothuizen TC, Damanik FFR, Anderson JM, *et al.* Tailoring the foreign body response for in situ vascular tissue engineering. *Tissue Eng Part C Methods* 2014; 21:436–446.
45. Mariani E, Lisignoli G, Borzi RM, Pulsatelli L. Biomaterials: foreign bodies or tuners for the immune response? *Int J Mol Sci* 2019; 20:E636.
46. Sengupta D, Waldman SD, Li S. From in vitro to in situ tissue engineering. *Ann Biomed Eng* 2014; 42:1537–1545.
47. Bayrak E, Yilgor Huri P. Engineering musculoskeletal tissue interfaces. *Front Mater* 2018; 5:24.
48. Ray A, Lee O, Win Z, *et al.* Anisotropic forces from spatially constrained focal adhesions mediate contact guidance directed cell migration. *Nat Commun* 2017; 8:14923.
49. Buskermolen ABC, Suresh H, Shishvan SS, *et al.* Entropic forces drive cellular contact guidance. *Biophys J* 2019; 116:1994–2008.
50. Schoenenberger AD, Foolen J, Moor P, *et al.* Substrate fiber alignment mediates tendon cell response to inflammatory signaling. *Acta Biomater* 2018; 71:306–317.
51. Ristori T, Notermans TMW, Foolen J, *et al.* Modelling the combined effects of collagen and cyclic strain on cellular orientation in collagenous tissues. *Sci Rep* 2018; 8:8518.
52. Chagnon-Lessard S, Jean-Ruel H, Godin M, Pelling AE. Cellular orientation is guided by strain gradients. *Integr Biol* 2017; 9:607–618.
53. Poduri A, Chang AH, Rafferty B, *et al.* Endothelial cells respond to the direction of mechanical stimuli through SMAD signaling to regulate coronary artery size. *Development* 2017; 144:3241–3252.
54. Wijesekara P, Ng WH, Feng M, Ren X. Bioengineering the innate vasculature of complex organs. *Curr Opin Organ Transplant* 2018; 23:657–663.
55. Gouveia RM, Koudouna E, Jester J, *et al.* Template curvature influences cell alignment to create improved human corneal tissue equivalents. *Adv Biosyst* 2017; 2017:1700135.
56. Pleuchot L, Marteau J, Guignandon A, *et al.* Curvotaxis directs cell migration through cell-scale curvature landscape. *Nat Commun* 2018; 9:3995.
57. Werner M, Kurniawan NA, Korus G, *et al.* Mesoscale substrate curvature overrules nanoscale contact guidance to direct bone marrow stromal cell migration. *J R Soc Interface* 2018; 15:20180162.
58. Tamiello C, Buskermolen ABC, Baaijens FPT, *et al.* Heading in the right direction: understanding cellular orientation responses to complex biophysical environments. *Cell Mol Bioeng* 2016; 9:12–37.
59. Kennedy KM, Bhaw-Luximon A, Jhurry D. Cell-matrix mechanical interaction in ■ electrospun polymeric scaffolds for tissue engineering: implications for scaffold design and performance. *Acta Biomater* 2017; 50:41–55.
- This article discusses in detail the ways in which mechanical interactions between cells and scaffolds or the extracellular matrix can influence tissue-engineering processes, as well as how such interactions can be taken into account for an informed design of scaffolds for tissue engineering.
60. Rinoldi C, Costantini M, Kijeńska-Gawrońska E, *et al.* Tendon tissue engineering: effects of mechanical and biochemical stimulation on stem cell alignment on cell-laden hydrogel yarns. *Adv Healthc Mater* 2019; 8:e1801218.
61. Prince E, Alizadehgiashi M, Campbell M, *et al.* Patterning of structurally ■ anisotropic composite hydrogel sheets. *Biomacromolecules* 2018; 19:1276–1284.
- This study reports the development of a novel method to fabricate cytocompatible hydrogel sheets with anisotropic structural properties, which represents an important advance towards structured tissue and organ engineering.
62. Zaitseva TS, Alcazar C, Zamani M, *et al.* Aligned nanofibrillar scaffolds for ■ controlled delivery of modified mRNA. *Tissue Eng Part A* 2018; 25:121–130.
- This study reports a unique and innovative approach of combining scaffold microstructure and mRNA release to enhance vascular regeneration.
63. Takahashi H, Shimizu T, Nakayama M, *et al.* The use of anisotropic cell sheets to control orientation during the self-organization of 3D muscle tissue. *Biomaterials* 2013; 34:7372–7380.
64. Liu C, Zhou Y, Sun M, *et al.* Light-induced cell alignment and harvest for anisotropic cell sheet technology. *ACS Appl Mater Interfaces* 2017; 9:36513–36524.
65. Kurniawan NA, Bouten CVC. Mechanobiology of the cell-matrix interplay: catching a glimpse of complexity via minimalistic models. *Extrem Mech Lett* 2018; 20:59–64.
66. Tandon N, Marolt D, Cimetta E, Vunjak-Novakovic G. Bioreactor engineering of stem cell environments. *Biotechnol Adv* 2013; 31:1020–1031.
67. Ahmed S, Chauhan VM, Ghaemmaghami AM, Aylott JW. New generation of ■ bioreactors that advance extracellular matrix modelling and tissue engineering. *Biotechnol Lett* 2019; 41:1–25.
- This article describes recent developments of bioreactor designs that bridge traditional in-vitro cell culture and in-vivo conditions by incorporating physiologically relevant culture environments.
68. Kropp C, Massai D, Zweigerdt R. Progress and challenges in large-scale expansion of human pluripotent stem cells. *Process Biochem* 2017; 59:244–254.
69. van Haften E, Bouten C, Kurniawan N. Vascular mechanobiology: towards control of in situ regeneration. *Cells* 2017; 6:19.
70. van Engeland NCA, Pollet AMAO, den Toonder JMJ, *et al.* A biomimetic microfluidic model to study signalling between endothelial and vascular smooth muscle cells under hemodynamic conditions. *Lab Chip* 2018; 18:1607–1620.
71. Sato K, Nitta M, Ogawa A. A microfluidic cell stretch device to investigate the effects of stretching stress on artery smooth muscle cell proliferation in pulmonary arterial hypertension. *Inventions* 2018; 4:1.
72. van Haften EE, Wissing TB, Rutten M, *et al.* Decoupling the effect of shear stress and stretch on tissue growth & remodeling in a vascular graft. *Tissue Eng Part C Methods* 2018; 24:418–429.
73. Seiden C, Fuller B. Role of bioreactor technology in tissue engineering for clinical use and therapeutic target design. *Bioengineering (Basel)* 2018; 5:32.